Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
Authors
Samuel J Klempner
Massachusetts General Hospital, Boston, MA;
Samuel J Klempner , Julia C. F. C. F. Quintanilha , Matthew Emmett , Ryon Graf , Alexa Betzig Schrock , Hanna Tukachinsky , Geoffrey R. Oxnard , Parvathi Myer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 52)
DOI
10.1200/JCO.2023.41.4_suppl.52
Abstract #
52
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tumor genomics and sidedness to predict outcomes in metastatic colorectal cancer (mCRC).
First Author: Patrick M Boland
Poster
2017 Gastrointestinal Cancers Symposium
Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer.
First Author: Alex Sorokin
Poster
2015 Gastrointestinal Cancers Symposium
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
First Author: Enrique Sanz-Garcia
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu